<?xml version='1.0' encoding='utf-8'?>
<document id="24259633"><sentence text="Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events."><entity charOffset="29-40" id="DDI-PubMed.24259633.s1.e0" text="montelukast" /><entity charOffset="45-54" id="DDI-PubMed.24259633.s1.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.24259633.s1.e0" e2="DDI-PubMed.24259633.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24259633.s1.e0" e2="DDI-PubMed.24259633.s1.e1" /></sentence><sentence text="To report the case of an HIV patient who developed neuropsychiatric disturbances when montelukast was added to her therapy containing efavirenz"><entity charOffset="86-97" id="DDI-PubMed.24259633.s2.e0" text="montelukast" /><entity charOffset="134-143" id="DDI-PubMed.24259633.s2.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.24259633.s2.e0" e2="DDI-PubMed.24259633.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24259633.s2.e0" e2="DDI-PubMed.24259633.s2.e1" /></sentence><sentence text="" /><sentence text="A 41-year-old woman with HIV infection had been on treatment with efavirenz, emtricitabine, and tenofovir disoproxil fumarate since 2007 with good tolerance"><entity charOffset="66-75" id="DDI-PubMed.24259633.s4.e0" text="efavirenz" /><entity charOffset="77-90" id="DDI-PubMed.24259633.s4.e1" text="emtricitabine" /><entity charOffset="96-125" id="DDI-PubMed.24259633.s4.e2" text="tenofovir disoproxil fumarate" /><pair ddi="false" e1="DDI-PubMed.24259633.s4.e0" e2="DDI-PubMed.24259633.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24259633.s4.e0" e2="DDI-PubMed.24259633.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24259633.s4.e0" e2="DDI-PubMed.24259633.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24259633.s4.e1" e2="DDI-PubMed.24259633.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24259633.s4.e1" e2="DDI-PubMed.24259633.s4.e2" /></sentence><sentence text=" In November 2011, montelukast was started for asthma and shortly thereafter neuropsychiatric symptoms appeared, consisting of disturbed sleep, vivid dreams, irritability, confusion, and concentration difficulties"><entity charOffset="19-30" id="DDI-PubMed.24259633.s5.e0" text="montelukast" /></sentence><sentence text=" In January 2012, 2 months after the introduction of montelukast, she continued to report unbearable symptoms without any improvement; so, montelukast was withdrawn and the psychiatric symptoms completely disappeared"><entity charOffset="53-64" id="DDI-PubMed.24259633.s6.e0" text="montelukast" /><entity charOffset="139-150" id="DDI-PubMed.24259633.s6.e1" text="montelukast" /><pair ddi="false" e1="DDI-PubMed.24259633.s6.e0" e2="DDI-PubMed.24259633.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24259633.s6.e0" e2="DDI-PubMed.24259633.s6.e1" /></sentence><sentence text="" /><sentence text="The combination of efavirenz and montelukast has not previously been associated with any pharmacokinetic interactions or worsening of neuropsychiatric symptoms"><entity charOffset="19-28" id="DDI-PubMed.24259633.s8.e0" text="efavirenz" /><entity charOffset="33-44" id="DDI-PubMed.24259633.s8.e1" text="montelukast" /><pair ddi="false" e1="DDI-PubMed.24259633.s8.e0" e2="DDI-PubMed.24259633.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24259633.s8.e0" e2="DDI-PubMed.24259633.s8.e1" /></sentence><sentence text=" This case report indicates the possibility of adverse effects developing when the 2 drugs are used together" /><sentence text=" These symptoms might either be related to a drug-drug interaction or increased by the similar side effect profiles of the 2 drugs" /><sentence text=" The higher score on the Karch-Lasagna scale suggests that an adverse effect is the more likely explanation" /><sentence text=" We cannot, however, rule out a drug interaction, given that efavirenz inhibits the CYP 2C9, 2C19, and 3A4 isoenzymes and CYP 3A4, 2C9, and 2C8 are involved in the metabolism of montelukast"><entity charOffset="61-70" id="DDI-PubMed.24259633.s12.e0" text="efavirenz" /><entity charOffset="178-189" id="DDI-PubMed.24259633.s12.e1" text="montelukast" /><pair ddi="false" e1="DDI-PubMed.24259633.s12.e0" e2="DDI-PubMed.24259633.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24259633.s12.e0" e2="DDI-PubMed.24259633.s12.e1" /></sentence><sentence text="" /><sentence text="Considering that efavirenz is frequently used in antiretroviral therapy and that neuropsychiatric symptoms can limit its use, clinicians should consider the possibility of worsening of these symptoms, such as mood disorders and abnormal dreams, when montelukast is introduced"><entity charOffset="17-26" id="DDI-PubMed.24259633.s14.e0" text="efavirenz" /><entity charOffset="250-261" id="DDI-PubMed.24259633.s14.e1" text="montelukast" /><pair ddi="false" e1="DDI-PubMed.24259633.s14.e0" e2="DDI-PubMed.24259633.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24259633.s14.e0" e2="DDI-PubMed.24259633.s14.e1" /></sentence><sentence text="" /></document>